Patents by Inventor Andrew Kenneth Takle

Andrew Kenneth Takle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Indazoles used to treat estrogen receptor beta mediated disorders
    Patent number: 7960563
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: March 5, 2008
    Date of Patent: June 14, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Compounds
    Patent number: 7956083
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Grant
    Filed: February 17, 2009
    Date of Patent: June 7, 2011
    Assignee: Glaxo Group Limited
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • COMPOUNDS
    Publication number: 20100324106
    Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Application
    Filed: February 17, 2009
    Publication date: December 23, 2010
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
  • IMIDAZOPYRIDINE DERIVATIVES AS ACID PUMP ANTAGONISTS
    Publication number: 20100311740
    Abstract: This invention relates to newly identified imidazopyridine compounds of formula (I), to the use of such compounds in treating GERD and the like.
    Type: Application
    Filed: June 28, 2006
    Publication date: December 9, 2010
    Inventors: Mark James Bamford, Richard Leonard Elliott, Gerard Martin Paul Giblin, Antoinette Naylor, Terence Aaron Chal, Andrew Kenneth Takle, Jason Witherington
  • Indazoles Used To Treat Estrogen Receptor Beta Mediated Disorders
    Publication number: 20100087502
    Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.
    Type: Application
    Filed: March 5, 2008
    Publication date: April 8, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
  • Pyridine derivatives as Raf kinase inhibitors
    Patent number: 7452906
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 18, 2008
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Mark James Bamford, David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Pyridylfurans and pyrroles as Raf kinase inhibitors
    Patent number: 7446106
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 4, 2008
    Assignee: SmithKline Beecham plc
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Piperazine derivatives useful for the treatment of gastrointestinal disorders
    Patent number: 7381728
    Abstract: The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ra, Rb, Rc, Rd, Re, Rf and Y are as defined in the specification. The compounds are partial or full agonists at the growth hormone secretagogue (GHS) receptors. Pharmaceutical compositions comprising the compounds methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
    Type: Grant
    Filed: July 26, 2005
    Date of Patent: June 3, 2008
    Assignee: Glaxo Group Limited
    Inventors: David Kenneth Dean, Alessandra Gaiba, Nigel Paul King, Andrew Kenneth Takle, Jason Witherington
  • Pyridine substituted furan derivatives as Raf kinase inhibitors
    Patent number: 7375105
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. Wherein X is O, CH2 CO, S or NH, or the moiety X—R1 is hydrogen; Y1 and Y2 independently represent CH or N; Ar is a mono- or fused bicyclic aromatic or heteroaromatic group which may be optionally substituted; one of X1 and X2 is selected from O, S or NR11 and the other is CH, wherein R11 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: May 20, 2008
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Nitrogen-containing heterocyclic compounds and their use as Raf inhibitors
    Patent number: 7297693
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 20, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Mark James Bamford, David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Pyridylfurans and pyrroles as Raf kinase inhibitors
    Patent number: 7297694
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Grant
    Filed: September 5, 2002
    Date of Patent: November 20, 2007
    Assignee: SmithKline Beechum P.L.C.
    Inventors: David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Imidazole-2-carboxamide derivatives as Raf kinase inhibitors
    Patent number: 7282500
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, use as Raf Kinase Inhibitors and treatment methods for neurotraumatic diseases and cancer.
    Type: Grant
    Filed: May 20, 2002
    Date of Patent: October 16, 2007
    Assignee: SmithKline Beecham P.L.C.
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Imidazol derivatives as Raf kinase inhibitors
    Patent number: 7235658
    Abstract: Compounds of formula (I): wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclylC1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except for hydrogen may be optionally substituted; R2 and R3 independently represent optionally substituted C1-6alkyl, or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted C3-7cycloalkyl or C3-7cycloalkenyl ring; or R2 and R3 together with the carbon atom to which they are attached form an optionally substituted 5 to 7-membered heterocyclyl ring containing up to 3 heteroatoms selected from N, O, S.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: June 26, 2007
    Assignee: SmithKline Beecham p.l.c.
    Inventors: Jon Graham Steadman, Andrew Kenneth Takle
  • Imidazole derivatives as Raf kinase inhibitors
    Patent number: 7199137
    Abstract: Novel compounds (I) and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy wherein Ar is a group of formula a) or b).
    Type: Grant
    Filed: September 19, 2001
    Date of Patent: April 3, 2007
    Assignee: SmithKline Beecham plc
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson
  • Pleuromutilin derivatives with antimicrobial activity
    Patent number: 7045524
    Abstract: Pleuromutilin compounds of the formula: are of use in anti-bacterial therapy.
    Type: Grant
    Filed: November 12, 2001
    Date of Patent: May 16, 2006
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle
  • Compounds
    Patent number: 7026336
    Abstract: Compounds of formula (I) wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; Y is NR10R11, NR10C(Z)NR10R11, NR10COOR11 or NR10SO2R11; Ar is phenyl or a 5- or 6-membered heteroaryl ring either of which may be optionally substituted; n is 0, 1, 2, 3 or 4; and R1, R2, R3, R4, R10 and R11 have the meanings given in the description; and pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 20, 2000
    Date of Patent: April 11, 2006
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Kenneth Dean, Peter John Lovell, Andrew Kenneth Takle
  • Imidazol-2-carboxamide derivatives as raf kinase inhibitors
    Patent number: 6987119
    Abstract: Compounds of formula (I): wherein X is O, CH2, S or NH, or the moiety X—R1 is hydrogen; V is CH or N; R1 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heterocyclyl, heterocyclyl-C1-6alkyl, heteroaryl, or heteroarylC1-6alkyl any of which except hydrogen may be optionally substituted; R2 and R3 independently represent hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl, arylC1-6alkyl, heteroaryl, heteroarylC1-6alkyl, heterocyclyl, or heterocyclylC1-6alkyl any one of which except hydrogen may be optionally substituted, or R2 and R3 together with the nitrogen atom to which they are attached form a 4- to 10-membered optionally substituted monocyclic or bicyclic ring; Ar is an aryl or heteroaryl ring either of which may be optionally substituted; one of X1 and X2 is N and the other is NR4, wherein R4 is hydrogen, C1-6alkyl, or arylC1-6alkyl; or pharmaceutically acceptable salts thereof; their use as inhibitors of Raf kinases and pharmaceutical compositions containing them.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: January 17, 2006
    Assignee: SmithKline Beecham P.L.C.
    Inventors: Alessandra Gaiba, Andrew Kenneth Takle, David Matthew Wilson
  • Quinoline derivatives as antibacterials
    Patent number: 6911442
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt and/or N-oxide thereof: corresponding novel medicaments, pharmaceutical compositions and/or methods of
    Type: Grant
    Filed: June 13, 2000
    Date of Patent: June 28, 2005
    Assignee: SmithKline Beecham p.l.c.
    Inventors: David Thomas Davies, Roger Edward Markwell, Neil David Pearson, Andrew Kenneth Takle
  • Pyridylfurans and pyrroles as raf kinase inhibitors
    Publication number: 20040254186
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 16, 2004
    Inventors: David Kenneth Dean, Antoinette Naylor, Andrew Kenneth Takle, David Matthew Wilson
  • Pyridine substituted furan derivatives as raf kinase inhibitors
    Publication number: 20040248896
    Abstract: Compounds and their use as pharmaceuticals particularly as Raf kinase inhibitors for the treatment of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy. Wherein X is O, CH2 CO, S or NH, or the moiety X—R1 is hydrogen; Y1 and Y2 independently represent CH or N; Ar is a mono- or fused bicyclic aromatic or heteroaromatic group which may be optionally substituted; one of X1 and X2 is selected from O, S or NR11 and the other is CH, wherein R11 is hydrogen, C1-6alkyl, aryl or arylC1-6alkyl.
    Type: Application
    Filed: March 4, 2004
    Publication date: December 9, 2004
    Inventors: David Kenneth Dean, Andrew Kenneth Takle, David Matthew Wilson